Steminent Biotherapeutics Inc. (TPEX:7729)

Market Cap	5.34B +379.2%
Revenue (ttm)	n/a
Net Income	-156.75M
EPS	-2.79
Shares Out	66.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Average Volume	725,797
Open	80.20
Previous Close	80.20
Day's Range	78.80 - 80.70
52-Week Range	15.25 - 95.60
Beta	n/a
RSI	52.15
Earnings Date	Apr 22, 2026

About Steminent Biotherapeutics

Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 47
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7729